Tactile Medical's 13% Lymphedema Quarter Meets a Third Straight AffloVest Slide — and a New Story About Funnels

The pump maker kept revenue guidance but quietly cut airway clearance to a mid-to-high single-digit decline; management's answer is less about adding reps and more about converting referrals

TCMD · Earnings Call · 2026-11-02

When a Double-Digit Grower Guides Flat and the Stock Says Otherwise

Tactile Systems Technology reported its third quarter on November 2, and on the surface it was more of the same: total revenue of $91.9 million, up 7.1%, with lymphedema up 13.1% to $81.8 million — the fifth consecutive quarter of above-market double-digit growth in the core franchise. Gross margin expanded 90 basis points to 76.7%, the twelfth straight quarter of year-over-year expansion. Full-year revenue guidance held at $360–366 million; adjusted EBITDA guidance went up to $50–52 million from a prior range, implying 12%–16% growth over 2025's $44.8 million. The stock, though, is not celebrating. Shares are down roughly 25% over the last 90 days and 28% from their early-July peak. The reason sits in the second product line. Airway clearance revenue fell 25.1% to $10 million, and management changed the full-year expectation from "approximately flat" to a mid-to-high single-digit decline. That is the tell: the company kept the top line intact only by letting the smaller, newer leg of the business get worse, twice.

"Temporary" Is Now a Three-Quarter Word

This is the second consecutive call in which the next-generation AffloVest rollout has been blamed for DME inventory congestion. In August, the CFO was categorical about the shape of the fix:

Q3, they'll start to burn through that inventory, and then starting in Q4, they'll start to pick back up on their overall ordering pattern. So we feel confident that we have good visibility now to what the current inventory is.
Elaine Birkemeyer, Chief Financial Officer · 2026-08-10

Three months later, the same dynamic is being re-dated. On Monday the CFO said DME customers are "taking longer than we initially expected to work through existing inventory … so we now assume a more gradual normalization of ordering." The CEO was blunter in Q&A: even where the new vest is selling well, “we just can't overcome the excess — the slowdown in the excess inventory burn with performance in the other DMEs.” — Sheri Dodd, Chief Executive Officer · 2026-11-02 In a concentrated, indirect distribution model, a handful of partners' balance sheets dictate the reported number. That is a structural feature, not a one-off — and it is the second time this year the company has had to re-time it. The inventory issues are described as timing, not demand, and that may well be true; but "timing" has now cost shareholders two guidance events. Worth recalling the arc. A year ago AffloVest was the hero — 16% of revenue versus 11% prior, and Sheri Dodd explicitly warned not to extrapolate: “we shouldn't be expecting that we're going to see this type of growth next year.” — Sheri Dodd, Chief Executive Officer · 2025-11-03 She was right, just not in the direction the model wanted. The growth engine became the drag. The guidance math is where the quarter actually lands. With $252.8 million booked year-to-date, the $360–366 million range implies roughly $107–113 million in Q4 against $104 million last year — about 3%–9% growth at a midpoint near 6%, versus 12% year-to-date. The company is guiding itself into a deceleration and asking investors to look through it.

The Story Moves From Feet on the Street to the Funnel

What is genuinely new in this call is not the AffloVest excuse; it is the strategic vocabulary. For several quarters the lymphedema narrative was headcount: more territory managers, a 1:1 rep-to-specialist model, CRM adoption, rep productivity. That story is now formally subordinated. In prepared remarks the CEO drew the line herself: “sustained growth in our lymphedema business is not solely a function of adding sales representatives.” — Sheri Dodd, Chief Executive Officer · 2026-11-02 In its place: a funnel story. Diagnose more patients, refer more of them, and — the operative phrase, ranked at the very top of this quarter's keyword set — convert referral to shipment. Management is replatforming the end-to-end order process with an AI-enabled order management system, stood up a strategic accounts team aimed at IDNs and national accounts, and hired a newly created COO, Steve Kiewiet, to own order operations and patient services. Early proof point: medical record review time down roughly 50%. The supporting metrics are decent — clinic visits up 19% year over year, referring clinics up more than 10% year-to-date, 13,000 clinicians educated in 2026 already 25% above all of 2025. And the portfolio is thickening: a 510(k) filed in October for Flexitouch Pro targeting a second-half 2027 launch, an expanded FDA clearance for the LymphaTech 3D Scanner now cleared to aid in assessment rather than measurement alone, and a VA pilot for MyoSleeve late in Q4. Note the global tape's curiosity here: 3D scanning keeps surfacing as a medical-device theme this quarter (Align Technology leaned on 3D printing in its own call), though Tactile's version is diagnostic measurement, not fabrication. But the company is deliberately sandbagging the timeline, and to its credit, says so: “I also want to temper some expectations that there isn't just a sudden hockey stick that happens because now we will have the Flexitouch Pro and the 3D Scanner.” — Sheri Dodd, Chief Executive Officer · 2026-11-02 The hockey stick disclaimer is a useful counterweight to a market that has twice been promised normalization that arrived late.

The Numbers Behind the Narrative

The P&L is genuinely better than the tape implies. Gross margin has climbed roughly six points in two years, which is what let adjusted EBITDA hold near flat ($14.3 million versus $14.4 million) despite a $6.9 million, 12.7% jump in operating expense. Year-to-date adjusted EBITDA is up about 35% to $29.5 million. The balance sheet is clean: $75.1 million of cash, no borrowings, $12 million of third-quarter operating cash flow funding $6.2 million of buybacks. Effective net cash of roughly $70 million remains a genuine strategic option. One number deserves investor attention as the funnel story plays out: receivables at 50.3% of revenue, up 8.4 points year over year. If the constraint on growth is documentation and order conversion, working capital is where that constraint will eventually show up — or where efficiency gains will show up first. And valuation is no longer distressed. Price to revenue near 1.9x, roughly double where it sat a year ago, is why a held guide plus a raised EBITDA guidance range was not enough. This is a company that still trades on its growth rate, and the growth rate it just implied for Q4 is a single-digit one.

The Tension to Watch

The bull case is that Tactile is converting a broken sales-capacity story into an operational-efficiency story at exactly the right moment, and that Flexitouch Pro plus a diagnostic pathway widen the moat through 2027–2029. The bear case is that every one of those catalysts is dated 2027 or later, the new COO is a fix that reports in future quarters, and the only near-term swing factor — a handful of DMEs burning down vest inventory — is explicitly outside management's control, as the CEO conceded. Add a Q4 that has to deliver roughly $110 million against a tough 16% lymphedema comparison, and the setup is a company asking for patience twice in one year. The funnel language is the right language. It now has to survive contact with a 2027 guidance call.